|
US6982260B1
(en)
|
1999-11-22 |
2006-01-03 |
Warner-Lambert Company |
Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
|
|
WO2002022605A1
(en)
*
|
2000-09-15 |
2002-03-21 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US6660731B2
(en)
|
2000-09-15 |
2003-12-09 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
US7473691B2
(en)
*
|
2000-09-15 |
2009-01-06 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
ATE407132T1
(de)
*
|
2000-12-05 |
2008-09-15 |
Vertex Pharma |
Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen
|
|
US6989385B2
(en)
*
|
2000-12-21 |
2006-01-24 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compounds useful as protein kinase inhibitors
|
|
UY27224A1
(es)
*
|
2001-03-23 |
2002-10-31 |
Bayer Corp |
Inhibidores de la rho-quinasa
|
|
US7034026B2
(en)
|
2001-04-10 |
2006-04-25 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
|
US7105667B2
(en)
*
|
2001-05-01 |
2006-09-12 |
Bristol-Myers Squibb Co. |
Fused heterocyclic compounds and use thereof
|
|
US7138404B2
(en)
*
|
2001-05-23 |
2006-11-21 |
Hoffmann-La Roche Inc. |
4-aminopyrimidine derivatives
|
|
US6939874B2
(en)
|
2001-08-22 |
2005-09-06 |
Amgen Inc. |
Substituted pyrimidinyl derivatives and methods of use
|
|
US7115617B2
(en)
|
2001-08-22 |
2006-10-03 |
Amgen Inc. |
Amino-substituted pyrimidinyl derivatives and methods of use
|
|
WO2003026664A1
(en)
*
|
2001-09-26 |
2003-04-03 |
Bayer Corporation |
2-phenylamino-4- (5-pyrazolylamino) -pyramidine derivatives as kinase inhibitors, in particular, src kinase inhibitors
|
|
BR0212841A
(pt)
|
2001-09-26 |
2004-08-03 |
Pharmacia Italia Spa |
Derivado ativo de aminoindazole como inibidores de cinase, processo para sua preparação e composições farmacêuticas que os contém
|
|
SE0104140D0
(sv)
|
2001-12-07 |
2001-12-07 |
Astrazeneca Ab |
Novel Compounds
|
|
US20030187026A1
(en)
|
2001-12-13 |
2003-10-02 |
Qun Li |
Kinase inhibitors
|
|
WO2003055866A1
(en)
*
|
2001-12-21 |
2003-07-10 |
Bayer Pharmaceuticals Corporation |
Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
|
|
ES2316756T3
(es)
*
|
2002-01-10 |
2009-04-16 |
F. Hoffmann-La Roche Ag |
Uso de un inhibidor de gsk-3beta en la fabricacion de un medicamento para incrementar la formacion osea.
|
|
TWI329105B
(en)
|
2002-02-01 |
2010-08-21 |
Rigel Pharmaceuticals Inc |
2,4-pyrimidinediamine compounds and their uses
|
|
WO2003066629A2
(en)
*
|
2002-02-06 |
2003-08-14 |
Vertex Pharmaceuticals Incorporated |
Heteroaryl compounds useful as inhibitors of gsk-3
|
|
DE60332433D1
(de)
|
2002-03-15 |
2010-06-17 |
Vertex Pharma |
Azolylaminoazine als proteinkinasehemmer
|
|
EP1485381B8
(en)
|
2002-03-15 |
2010-05-12 |
Vertex Pharmaceuticals Incorporated |
Azolylaminoazine as inhibitors of protein kinases
|
|
US20040009981A1
(en)
|
2002-03-15 |
2004-01-15 |
David Bebbington |
Compositions useful as inhibitors of protein kinases
|
|
US7223738B2
(en)
|
2002-04-08 |
2007-05-29 |
Merck & Co., Inc. |
Inhibitors of Akt activity
|
|
JPWO2003104230A1
(ja)
|
2002-06-07 |
2005-10-06 |
協和醗酵工業株式会社 |
二環性ピリミジン誘導体
|
|
MY141867A
(en)
*
|
2002-06-20 |
2010-07-16 |
Vertex Pharma |
Substituted pyrimidines useful as protein kinase inhibitors
|
|
AU2003261204A1
(en)
*
|
2002-07-23 |
2004-02-09 |
Smithkline Beecham Corporation |
Pyrazolopyrimidines as kinase inhibitors
|
|
HRP20050089B1
(hr)
|
2002-07-29 |
2015-06-19 |
Rigel Pharmaceuticals |
Upotreba 2,4 pirimidindiaminskog spoja za proizvodnju lijeka za lijeäśenje ili sprjeäśavanje autoimunosne bolesti
|
|
CN1319968C
(zh)
*
|
2002-08-02 |
2007-06-06 |
沃泰克斯药物股份有限公司 |
用作gsk－3的抑制剂的吡唑组合物
|
|
EP1739087A1
(en)
*
|
2002-08-02 |
2007-01-03 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of gsk-3
|
|
FR2844267B1
(fr)
*
|
2002-09-05 |
2008-02-15 |
Aventis Pharma Sa |
Nouveaux derives d'aminoindazoles a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
JP4648703B2
(ja)
|
2002-09-05 |
2011-03-09 |
アベンティス・ファーマ・ソシエテ・アノニム |
医薬としての新規なアミノインダゾール誘導体及びこれらを含む医薬組成物
|
|
WO2004030672A1
(en)
*
|
2002-10-02 |
2004-04-15 |
Merck Patent Gmbh |
Use of 4 amino-quinazolines as anti cancer agents
|
|
JP4690043B2
(ja)
|
2002-10-04 |
2011-06-01 |
プラナ バイオテクノロジー リミティッド |
神経に対し活性な化合物
|
|
KR100490893B1
(ko)
*
|
2002-10-11 |
2005-05-23 |
(주) 비엔씨바이오팜 |
2-메톡시-1,3,5-트리아진 유도체, 그 제조방법 및 이를 포함하는 항바이러스용 약학적 조성물
|
|
GB0226583D0
(en)
*
|
2002-11-14 |
2002-12-18 |
Cyclacel Ltd |
Compounds
|
|
US7309701B2
(en)
|
2002-11-19 |
2007-12-18 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
|
FR2847253B1
(fr)
*
|
2002-11-19 |
2007-05-18 |
Aventis Pharma Sa |
Nouveaux derives de pyridazinones a titre de medicaments et compositions pharmaceutiques les renfermant
|
|
US7462613B2
(en)
|
2002-11-19 |
2008-12-09 |
Sanofi-Aventis Deutschland Gmbh |
Pyridazinone derivatives as pharmaceuticals and pharmaceutical compositions containing them
|
|
EA013811B1
(ru)
*
|
2002-11-21 |
2010-08-30 |
Новартис Вэксинес Энд Дайэгностикс, Инк. |
2,4,6-тризамещённые пиримидины, являющиеся ингибиторами фосфотидилинозитол(pi)-3-киназы, и их применение при лечении рака
|
|
US7601718B2
(en)
*
|
2003-02-06 |
2009-10-13 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of protein kinases
|
|
US7157455B2
(en)
*
|
2003-02-10 |
2007-01-02 |
Hoffmann-La Roche Inc. |
4-Aminopyrimidine-5-one derivatives
|
|
EP1644338A1
(en)
*
|
2003-04-01 |
2006-04-12 |
Aponetics AG |
2, 4, 6-trisubstituted pyrimidine derivatives useful for the treatment of neoplastic and autoimmune diseases
|
|
ATE401080T1
(de)
*
|
2003-06-02 |
2008-08-15 |
Astrazeneca Ab |
(3-((chinazolin-4-yl)amino)-1h-pyrazol-1- yl)acetamid derivate und verwandte verbindungen als aurora kinase inhibitoren zur behandlung von proliferativen erkrankungen wie krebs
|
|
WO2004112719A2
(en)
|
2003-06-19 |
2004-12-29 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
WO2006074147A2
(en)
|
2005-01-03 |
2006-07-13 |
Myriad Genetics, Inc. |
Nitrogen containing bicyclic compounds and therapeutical use thereof
|
|
TWI372050B
(en)
*
|
2003-07-03 |
2012-09-11 |
Astex Therapeutics Ltd |
(morpholin-4-ylmethyl-1h-benzimidazol-2-yl)-1h-pyrazoles
|
|
US8309562B2
(en)
|
2003-07-03 |
2012-11-13 |
Myrexis, Inc. |
Compounds and therapeutical use thereof
|
|
AU2004253967B2
(en)
*
|
2003-07-03 |
2010-02-18 |
Cytovia, Inc. |
4-arylamino-quinazolines as activators of caspases and inducers of apoptosis
|
|
GB0315966D0
(en)
*
|
2003-07-08 |
2003-08-13 |
Cyclacel Ltd |
Compounds
|
|
CA2532965C
(en)
|
2003-07-22 |
2013-05-14 |
Astex Therapeutics Limited |
3, 4-disubstituted 1h-pyrazole compounds and their use as cyclin dependent kinases (cdk) and glycogen synthase kinase-3 (gsk-3) modulators
|
|
WO2005012294A1
(en)
|
2003-07-30 |
2005-02-10 |
Rigel Pharmaceuticals, Inc. |
2,4-pyrimidinediamine compounds for use in the treatment or prevention of autoimmune diseases
|
|
EP1648875A1
(en)
*
|
2003-07-30 |
2006-04-26 |
Cyclacel Limited |
2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
|
|
US20050221357A1
(en)
*
|
2003-09-19 |
2005-10-06 |
Mark Shannon |
Normalization of gene expression data
|
|
US7417726B2
(en)
*
|
2003-09-19 |
2008-08-26 |
Applied Biosystems Inc. |
Normalization of data using controls
|
|
US20060024690A1
(en)
*
|
2003-09-19 |
2006-02-02 |
Kao H P |
Normalization of data using controls
|
|
WO2005030131A2
(en)
*
|
2003-09-23 |
2005-04-07 |
Replidyne, Inc |
Bis-quinazoline compounds for the treatment of bacterial infections
|
|
CA2542522A1
(en)
|
2003-10-17 |
2005-05-06 |
Astrazeneca Ab |
4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
|
|
US7592340B2
(en)
*
|
2003-12-04 |
2009-09-22 |
Vertex Pharmaceuticals Incorporated |
Quinoxalines useful as inhibitors of protein kinases
|
|
CN1914204A
(zh)
*
|
2003-12-09 |
2007-02-14 |
弗特克斯药品有限公司 |
萘啶衍生物及其作为毒蕈碱性受体调节剂的用途
|
|
EP1694686A1
(en)
*
|
2003-12-19 |
2006-08-30 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
TW200530235A
(en)
|
2003-12-24 |
2005-09-16 |
Renovis Inc |
Bicycloheteroarylamine compounds as ion channel ligands and uses thereof
|
|
AU2005212438A1
(en)
|
2004-02-11 |
2005-08-25 |
Amgen Inc. |
Vanilloid receptor ligands and their use in treatments
|
|
US20080050314A1
(en)
*
|
2004-02-26 |
2008-02-28 |
Bayer Healthcare Ag |
Diagnostics and Therapeutics for Diseases Associated With Glycogen Synthase Kinase 3 Beta (Gsk3b)
|
|
JP4875978B2
(ja)
*
|
2004-03-15 |
2012-02-15 |
武田薬品工業株式会社 |
アミノフェニルプロパン酸誘導体
|
|
EP1732541A4
(en)
*
|
2004-04-07 |
2008-03-05 |
Takeda Pharmaceutical |
CYCLIC COMPOUNDS
|
|
EP1742921A2
(en)
*
|
2004-04-21 |
2007-01-17 |
AstraZeneca AB |
Pyrazole derivatives useful for the treatment of cancer
|
|
US20050250829A1
(en)
*
|
2004-04-23 |
2005-11-10 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
CA2564355C
(en)
*
|
2004-05-07 |
2012-07-03 |
Amgen Inc. |
Protein kinase modulators and method of use
|
|
US7793137B2
(en)
|
2004-10-07 |
2010-09-07 |
Cisco Technology, Inc. |
Redundant power and data in a wired data telecommunincations network
|
|
US20050255485A1
(en)
*
|
2004-05-14 |
2005-11-17 |
Livak Kenneth J |
Detection of gene duplications
|
|
AU2005243175B2
(en)
*
|
2004-05-14 |
2011-12-01 |
Millennium Pharmaceuticals, Inc. |
Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase
|
|
AU2005245877B2
(en)
*
|
2004-05-14 |
2010-06-03 |
Vertex Pharmaceuticals, Incorporated |
Prodrugs of pyrrolylpyrimidine ERK protein kinase inhibitors
|
|
SI1771450T1
(sl)
*
|
2004-05-14 |
2008-06-30 |
Millennium Pharm Inc |
Spojine in postopki za inhibiranje mitotične progresije z inhibicijo kinaze Aurora
|
|
AU2012200416B2
(en)
*
|
2004-05-14 |
2014-07-31 |
Millennium Pharmaceuticals, Inc. |
"Compounds and methods for inhibiting mitotic progression by inhibition of Aurora kinase"
|
|
CA2567352A1
(en)
*
|
2004-05-20 |
2005-12-01 |
Bayer Pharmaceuticals Corporation |
5-anilino-4-heteroarylpyrazole derivatives useful for the treatment of diabetes
|
|
CN1973247A
(zh)
*
|
2004-05-27 |
2007-05-30 |
纳幕尔杜邦公司 |
光聚合物保护层的显影剂
|
|
WO2006007532A2
(en)
*
|
2004-07-01 |
2006-01-19 |
Synta Pharmaceuticals Corp. |
2-substituted heteroaryl compounds
|
|
US20060025406A1
(en)
*
|
2004-07-06 |
2006-02-02 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c- Met activity
|
|
WO2006023931A2
(en)
*
|
2004-08-18 |
2006-03-02 |
Takeda San Diego, Inc. |
Kinase inhibitors
|
|
US7285569B2
(en)
|
2004-09-24 |
2007-10-23 |
Hoff Hoffmann-La Roche Inc. |
Tricycles, their manufacture and use as pharmaceutical agents
|
|
AR050948A1
(es)
|
2004-09-24 |
2006-12-06 |
Hoffmann La Roche |
Derivados de ftalazinona; su obtencion y su utilizacion en la fabricacion de medicamentos para el tratamiento del cancer.
|
|
WO2006035067A2
(en)
*
|
2004-09-30 |
2006-04-06 |
Tibotec Pharmaceuticals Ltd. |
Hiv inhibiting 5-heterocyclyl pyrimidines
|
|
JP5046943B2
(ja)
*
|
2004-09-30 |
2012-10-10 |
テイボテク・フアーマシユーチカルズ |
Ｈｉｖ阻害性５−置換ピリミジン
|
|
ES2371924T3
(es)
*
|
2004-09-30 |
2012-01-11 |
Tibotec Pharmaceuticals |
Pirimidinas 5-carbo o heterociclo- sustituidas que inhiben el hiv.
|
|
EP1812439B2
(en)
*
|
2004-10-15 |
2017-12-06 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
US7491720B2
(en)
|
2004-10-29 |
2009-02-17 |
Banyu Pharmaceutical Co., Ltd. |
Aminopyridine derivatives having Aurora A selective inhibitory action
|
|
AR051467A1
(es)
*
|
2004-10-29 |
2007-01-17 |
Banyu Pharma Co Ltd |
Derivados de aminopiridina con accion inhibitoria selectiva de la aurora quinasa a
|
|
US7767680B2
(en)
|
2004-11-03 |
2010-08-03 |
Vertex Pharmaceuticals Incorporated |
Ion channel modulators and methods of use
|
|
CN101084214A
(zh)
*
|
2004-11-17 |
2007-12-05 |
迈卡纳治疗股份有限公司 |
激酶抑制剂
|
|
SI1814878T1
(sl)
|
2004-11-24 |
2012-06-29 |
Rigel Pharmaceuticals Inc |
Spojine spiro-2,4-pirimidindiamina in njihova uporaba
|
|
US20060128710A1
(en)
*
|
2004-12-09 |
2006-06-15 |
Chih-Hung Lee |
Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof
|
|
JP2008525422A
(ja)
*
|
2004-12-23 |
2008-07-17 |
ファイザー・プロダクツ・インク |
抗癌剤として有用な複素芳香族誘導体
|
|
ATE519759T1
(de)
|
2004-12-30 |
2011-08-15 |
Exelixis Inc |
Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
|
|
MX2007008008A
(es)
*
|
2004-12-30 |
2007-11-12 |
Astex Therapeutics Ltd |
Compuestos de pirazol que modulan la actividad de las cinasas cdk, gsk y aurora.
|
|
US8258145B2
(en)
|
2005-01-03 |
2012-09-04 |
Myrexis, Inc. |
Method of treating brain cancer
|
|
AU2006206458B2
(en)
|
2005-01-19 |
2012-10-25 |
Rigel Pharmaceuticals, Inc. |
Prodrugs of 2,4-pyrimidinediamine compounds and their uses
|
|
US8404718B2
(en)
|
2005-01-21 |
2013-03-26 |
Astex Therapeutics Limited |
Combinations of pyrazole kinase inhibitors
|
|
AR054425A1
(es)
|
2005-01-21 |
2007-06-27 |
Astex Therapeutics Ltd |
Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
|
|
ATE451363T1
(de)
*
|
2005-01-26 |
2009-12-15 |
Schering Corp |
3-(indazol-5-yl)-(1,2,4)triazinderivate und verwandte verbindungen als proteinkinaseinhibitoren zur behandlung von krebs
|
|
BRPI0606793A8
(pt)
|
2005-02-04 |
2018-03-13 |
Astrazeneca Ab |
composto ou um sal farmaceuticamente aceitável do mesmo, processo para a preparação e uso do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de câncer e para a produção de um efeito anti-proliferativo em um animal de sangue quente, e, composição farmacêutica
|
|
ES2347172T3
(es)
*
|
2005-02-16 |
2010-10-26 |
Astrazeneca Ab |
Compuestos quimicos.
|
|
SI1853588T1
(sl)
*
|
2005-02-16 |
2008-10-31 |
Astrazeneca Ab |
Kemične spojine
|
|
US20080188483A1
(en)
*
|
2005-03-15 |
2008-08-07 |
Irm Llc |
Compounds and Compositions as Protein Kinase Inhibitors
|
|
WO2006100461A1
(en)
*
|
2005-03-23 |
2006-09-28 |
Astrazeneca Ab |
2-AZETIDINYL-4-(lH-PYRAZOL-3-YLAMINO)PYRIMIDINES AS INHIBITORS OF INSULIN-LIKE GROWTH FACTOR-I RECEPTOR ACTIVITY
|
|
US7402596B2
(en)
|
2005-03-24 |
2008-07-22 |
Renovis, Inc. |
Bicycloheteroaryl compounds as P2X7 modulators and uses thereof
|
|
JP2008534662A
(ja)
*
|
2005-04-05 |
2008-08-28 |
アストラゼネカ アクチボラグ |
抗癌剤として使用されるピリミジン誘導体
|
|
GB0507347D0
(en)
*
|
2005-04-12 |
2005-05-18 |
Astrazeneca Ab |
Chemical compounds
|
|
KR20070113286A
(ko)
|
2005-04-14 |
2007-11-28 |
에프. 호프만-라 로슈 아게 |
아미노피라졸 유도체, 이의 제조 및 약학 제제로서의 용도
|
|
CN101208093A
(zh)
*
|
2005-04-27 |
2008-06-25 |
阿斯利康(瑞典)有限公司 |
吡唑-嘧啶衍生物在治疗疼痛中的用途
|
|
AU2006241825A1
(en)
*
|
2005-04-28 |
2006-11-09 |
Mitsubishi Tanabe Pharma Corporation |
Cyanopyridine derivative and use thereof as medicine
|
|
MX2007013595A
(es)
|
2005-05-04 |
2008-01-24 |
Renovis Inc |
Compuestos heterociclicos fusionados y composiciones y usos de estos.
|
|
US20080207594A1
(en)
|
2005-05-04 |
2008-08-28 |
Davelogen Aktiengesellschaft |
Use of Gsk-3 Inhibitors for Preventing and Treating Pancreatic Autoimmune Disorders
|
|
CN101218229A
(zh)
*
|
2005-05-05 |
2008-07-09 |
阿斯利康(瑞典)有限公司 |
吡唑基-氨基取代的嘧啶及其在癌症治疗中的应用
|
|
US20080287437A1
(en)
*
|
2005-05-16 |
2008-11-20 |
Astrazeneca Ab |
Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
|
|
US20070203161A1
(en)
|
2006-02-24 |
2007-08-30 |
Rigel Pharmaceuticals, Inc. |
Compositions and methods for inhibition of the jak pathway
|
|
BRPI0610876B8
(pt)
|
2005-06-08 |
2021-05-25 |
Rigel Pharmaceuticals Inc |
composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel
|
|
NZ564222A
(en)
|
2005-06-14 |
2011-10-28 |
Taigen Biotechnology Co Ltd |
Pyrimidine compounds
|
|
US8193206B2
(en)
|
2005-06-14 |
2012-06-05 |
Taigen Biotechnology Co., Ltd. |
Pyrimidine compounds
|
|
EP1746096A1
(en)
|
2005-07-15 |
2007-01-24 |
4Sc Ag |
2-Arylbenzothiazole analogues and uses thereof in the treatment of cancer
|
|
ATE542814T1
(de)
*
|
2005-08-18 |
2012-02-15 |
Vertex Pharma |
Pyrazinkinaseinhibitoren
|
|
WO2007023382A2
(en)
*
|
2005-08-25 |
2007-03-01 |
Pfizer Inc. |
Pyrimidine amino pyrazole compounds, potent kinase inhibitors
|
|
EP2258358A3
(en)
|
2005-08-26 |
2011-09-07 |
Braincells, Inc. |
Neurogenesis with acetylcholinesterase inhibitor
|
|
EP2275095A3
(en)
|
2005-08-26 |
2011-08-17 |
Braincells, Inc. |
Neurogenesis by muscarinic receptor modulation
|
|
CN101316587B
(zh)
*
|
2005-09-30 |
2013-04-03 |
迈卡纳治疗股份有限公司 |
取代的吡唑化合物
|
|
KR101487027B1
(ko)
*
|
2005-09-30 |
2015-01-28 |
미카나 테라퓨틱스, 인크. |
치환된 피라졸 화합물
|
|
US8119655B2
(en)
|
2005-10-07 |
2012-02-21 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
EP1940389A2
(en)
|
2005-10-21 |
2008-07-09 |
Braincells, Inc. |
Modulation of neurogenesis by pde inhibition
|
|
JP2009513615A
(ja)
|
2005-10-28 |
2009-04-02 |
アストラゼネカ アクチボラグ |
癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体
|
|
AU2006308889A1
(en)
|
2005-10-31 |
2007-05-10 |
Braincells, Inc. |
GABA receptor mediated modulation of neurogenesis
|
|
NZ567858A
(en)
*
|
2005-11-01 |
2011-08-26 |
Array Biopharma Inc |
Pyridine compounds useful as Glucokinase activators
|
|
MX2008005814A
(es)
*
|
2005-11-03 |
2008-10-15 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de cinasa.
|
|
US20070179125A1
(en)
*
|
2005-11-16 |
2007-08-02 |
Damien Fraysse |
Aminopyrimidines useful as kinase inhibitors
|
|
US8546404B2
(en)
*
|
2005-12-13 |
2013-10-01 |
Merck Sharp & Dohme |
Compounds that are ERK inhibitors
|
|
US7572809B2
(en)
*
|
2005-12-19 |
2009-08-11 |
Hoffmann-La Roche Inc. |
Isoquinoline aminopyrazole derivatives
|
|
US8399442B2
(en)
|
2005-12-30 |
2013-03-19 |
Astex Therapeutics Limited |
Pharmaceutical compounds
|
|
US20080058312A1
(en)
*
|
2006-01-11 |
2008-03-06 |
Angion Biomedica Corporation |
Modulators of hepatocyte growth factor/c-Met activity
|
|
JO2660B1
(en)
|
2006-01-20 |
2012-06-17 |
نوفارتيس ايه جي |
Pi-3 inhibitors and methods of use
|
|
JP2009528280A
(ja)
*
|
2006-02-16 |
2009-08-06 |
シェーリング コーポレイション |
Ｅｒｋインヒビターとしてのピロリジン誘導体
|
|
US20100216734A1
(en)
|
2006-03-08 |
2010-08-26 |
Braincells, Inc. |
Modulation of neurogenesis by nootropic agents
|
|
PE20080145A1
(es)
*
|
2006-03-21 |
2008-02-11 |
Janssen Pharmaceutica Nv |
Tetrahidro-pirimidoazepinas como moduladores de trpv1
|
|
CN101405283B
(zh)
|
2006-03-30 |
2014-06-18 |
泰博特克药品有限公司 |
Hiv抑制性5-酰氨基取代的嘧啶类化合物
|
|
CA2644910C
(en)
*
|
2006-03-31 |
2014-01-28 |
Abbott Laboratories |
Indazole compounds
|
|
US20090286803A1
(en)
|
2006-04-07 |
2009-11-19 |
Manley Paul W |
Combination comprising a) a pyrimidylaminobenzamide compound, and b) a thr315lle kinase inhibitor
|
|
CN101534826A
(zh)
|
2006-04-14 |
2009-09-16 |
普拉纳生物技术有限公司 |
治疗与年龄相关的黄斑变性（amd）的方法
|
|
US8101621B2
(en)
|
2006-04-27 |
2012-01-24 |
Msd K.K. |
Aminopyridine derivatives having aurora a selective inhibitory action
|
|
JP2009536667A
(ja)
|
2006-05-09 |
2009-10-15 |
ブレインセルス，インコーポレイティド |
５ｈｔ受容体介在性の神経新生
|
|
EP2382975A3
(en)
|
2006-05-09 |
2012-02-29 |
Braincells, Inc. |
Neurogenesis by modulating angiotensin
|
|
RS53230B
(sr)
|
2006-06-27 |
2014-08-29 |
Takeda Pharmaceutical Company Limited |
Kondenzovana ciklična jedinjenja kao modulatori gpr40 receptora
|
|
EP2043635A2
(en)
*
|
2006-06-29 |
2009-04-08 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
JP5523829B2
(ja)
|
2006-06-29 |
2014-06-18 |
アステックス、セラピューティックス、リミテッド |
複合薬剤
|
|
EP2036894A4
(en)
*
|
2006-06-30 |
2011-01-12 |
Kyowa Hakko Kirin Co Ltd |
AURORA INHIBITOR
|
|
TW200817391A
(en)
*
|
2006-06-30 |
2008-04-16 |
Astrazeneca Ab |
Novel compounds
|
|
EP2043651A2
(en)
|
2006-07-05 |
2009-04-08 |
Exelixis, Inc. |
Methods of using igf1r and abl kinase modulators
|
|
EP2061767B1
(de)
|
2006-08-08 |
2014-12-17 |
Sanofi |
Arylaminoaryl-alkyl-substituierte Imidazolidin-2,4-dione, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende Arzneimittel und ihre Verwendung
|
|
US7718648B2
(en)
*
|
2006-08-09 |
2010-05-18 |
Millennium Pharmaceuticals, Inc. |
Pyridobenzazepine compounds and methods for inhibiting mitotic progression
|
|
US7635168B2
(en)
*
|
2006-08-11 |
2009-12-22 |
Hall David R |
Degradation assembly shield
|
|
JP2008081492A
(ja)
*
|
2006-08-31 |
2008-04-10 |
Banyu Pharmaceut Co Ltd |
オーロラａ選択的阻害作用を有する新規アミノピリジン誘導体
|
|
AU2007292848A1
(en)
|
2006-09-08 |
2008-03-13 |
Braincells, Inc. |
Combinations containing a 4-acylaminopyridine derivative
|
|
US20100184806A1
(en)
|
2006-09-19 |
2010-07-22 |
Braincells, Inc. |
Modulation of neurogenesis by ppar agents
|
|
EP2223925A1
(en)
*
|
2006-10-09 |
2010-09-01 |
Takeda Pharmaceutical Company Limited |
Kinase inhibitors
|
|
SG158147A1
(en)
|
2006-10-09 |
2010-01-29 |
Takeda Pharmaceutical |
Kinase inhibitors
|
|
EP2073807A1
(en)
|
2006-10-12 |
2009-07-01 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
WO2008044041A1
(en)
|
2006-10-12 |
2008-04-17 |
Astex Therapeutics Limited |
Pharmaceutical combinations
|
|
WO2008053812A1
(en)
*
|
2006-10-27 |
2008-05-08 |
Mitsubishi Tanabe Pharma Corporation |
Cyanopyridine derivative and medicinal use thereof
|
|
CA2668429A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Vertex Pharmaceuticals Incorporated |
Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
|
|
CL2007003244A1
(es)
|
2006-11-16 |
2008-04-04 |
Millennium Pharm Inc |
Compuestos derivados de pirimido[5,4-d][2]benzazepina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
|
|
ES2347721T3
(es)
*
|
2006-12-19 |
2010-11-03 |
Vertex Pharmaceuticals, Inc. |
Aminopirimidinas utiles como inhibidores de proteina quinasas.
|
|
AU2007341228B2
(en)
*
|
2006-12-29 |
2013-04-18 |
Janssen Sciences Ireland Uc |
HIV inhibiting 5,6-substituted pyrimidines
|
|
AU2007341227C1
(en)
*
|
2006-12-29 |
2013-08-29 |
Janssen Sciences Ireland Uc |
HIV inhibiting 6-substituted pyrimidines
|
|
WO2008098058A1
(en)
|
2007-02-06 |
2008-08-14 |
Novartis Ag |
Pi 3-kinase inhibitors and methods of their use
|
|
EP2133095A4
(en)
|
2007-03-05 |
2012-09-26 |
Kyowa Hakko Kirin Co Ltd |
PHARMACEUTICAL COMPOSITION
|
|
EP2134709A1
(en)
|
2007-03-09 |
2009-12-23 |
Vertex Pharmaceuticals, Inc. |
Aminopyridines useful as inhibitors of protein kinases
|
|
EP2137183B1
(en)
*
|
2007-03-09 |
2011-09-28 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
AU2008226457B2
(en)
*
|
2007-03-09 |
2014-03-20 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as inhibitors of protein kinases
|
|
WO2008115973A2
(en)
*
|
2007-03-20 |
2008-09-25 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
WO2008117050A1
(en)
*
|
2007-03-27 |
2008-10-02 |
Astrazeneca Ab |
Pyrazolyl-amino-substituted pyrazines and their use for the treatment of cancer
|
|
NZ580343A
(en)
*
|
2007-04-13 |
2012-03-30 |
Vertex Pharma |
Aminopyrimidines useful as kinase inhibitors
|
|
JP2010524911A
(ja)
*
|
2007-04-18 |
2010-07-22 |
アストラゼネカ アクチボラグ |
５−アミノピラゾール−３−イル−３Ｈ−イミダゾ［４，５−ｂ］ピリジン誘導体と癌の治療のためのその使用
|
|
CN101678215B
(zh)
|
2007-04-18 |
2014-10-01 |
辉瑞产品公司 |
用于治疗异常细胞生长的磺酰胺衍生物
|
|
MX2009011811A
(es)
*
|
2007-05-02 |
2010-01-14 |
Vertex Pharma |
Aminopirimidinas utiles como inhibidores de cinasa.
|
|
JP5389785B2
(ja)
*
|
2007-05-02 |
2014-01-15 |
バーテックス ファーマシューティカルズ インコーポレイテッド |
キナーゼ阻害剤として有用なチアゾールおよびピラゾール
|
|
CA2694381A1
(en)
*
|
2007-05-02 |
2008-11-13 |
Vertex Pharmaceuticals Incorporated |
Aminopyrimidines useful as kinase inhibitors
|
|
UA99459C2
(en)
*
|
2007-05-04 |
2012-08-27 |
Астразенека Аб |
9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
|
|
WO2008135786A1
(en)
*
|
2007-05-04 |
2008-11-13 |
Astrazeneca Ab |
Amino-thiazolyl- pyrimidine derivatives and their use for the treatment of cancer
|
|
EP2164842A2
(en)
*
|
2007-05-24 |
2010-03-24 |
Vertex Pharmaceuticals Incorporated |
Thiazoles and pyrazoles useful as kinase inhibitors
|
|
KR101294731B1
(ko)
*
|
2007-06-04 |
2013-08-16 |
삼성디스플레이 주식회사 |
어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
|
|
EP2166849A4
(en)
*
|
2007-06-11 |
2010-09-15 |
Miikana Therapeutics Inc |
SUBSTITUTED PYRAZOL COMPOUNDS
|
|
US20090274698A1
(en)
*
|
2007-07-06 |
2009-11-05 |
Shripad Bhagwat |
Combination anti-cancer therapy
|
|
WO2009007753A2
(en)
*
|
2007-07-11 |
2009-01-15 |
Astrazeneca Ab |
4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
|
|
US8415340B2
(en)
*
|
2007-07-25 |
2013-04-09 |
Bristol-Myers Squibb Company |
Triazine kinase inhibitors
|
|
WO2009013545A2
(en)
*
|
2007-07-26 |
2009-01-29 |
Astrazeneca Ab |
Chemical compounds
|
|
TW200906818A
(en)
*
|
2007-07-31 |
2009-02-16 |
Astrazeneca Ab |
Chemical compounds
|
|
NZ582879A
(en)
*
|
2007-07-31 |
2012-03-30 |
Vertex Pharma |
Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
|
|
EP2025674A1
(de)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
|
WO2009027736A2
(en)
*
|
2007-08-27 |
2009-03-05 |
Astrazeneca Ab |
2,4 diaminopyrimid'lnes for the treatment of myeloproliferative disorders and cancer
|
|
EP2573087A1
(en)
|
2007-09-21 |
2013-03-27 |
Array Biopharma, Inc. |
Pyridin-2-yl-amino-1,2,4-thiadiazole derivatives as glucokinase activators for the treatment of diabetes mellitus
|
|
WO2009049157A1
(en)
|
2007-10-11 |
2009-04-16 |
Smithkline Beecham Corporation |
Novel seh inhibitors and their use
|
|
WO2009078999A1
(en)
|
2007-12-17 |
2009-06-25 |
Janssen Pharmaceutica N.V. |
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of trpv1
|
|
US20090270418A1
(en)
*
|
2008-01-09 |
2009-10-29 |
Marianne Sloss |
Pyrazole pyrazine amine compounds as kinase inhibitors, compositions thereof and methods of treatment therewith
|
|
WO2009097995A1
(de)
*
|
2008-02-07 |
2009-08-13 |
Sanofi-Aventis |
Neue phenyl-substituierte imidazolidine, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US8716483B2
(en)
*
|
2008-02-21 |
2014-05-06 |
Merck Sharp & Dohme Corp. |
Compounds that are ERK inhibitors
|
|
EP2254888B1
(en)
*
|
2008-02-22 |
2014-12-24 |
Msd K.K. |
Novel aminopyridine derivatives having aurora a selective inhibitory action
|
|
DK2268635T3
(en)
|
2008-04-21 |
2015-09-14 |
Taigen Biotechnology Co Ltd |
Heterocyclic Compounds
|
|
US8844033B2
(en)
|
2008-05-27 |
2014-09-23 |
The Trustees Of Columbia University In The City Of New York |
Systems, methods, and media for detecting network anomalies using a trained probabilistic model
|
|
KR20110017445A
(ko)
*
|
2008-06-11 |
2011-02-21 |
아스트라제네카 아베 |
암 및 골수증식성 장애의 치료에 유용한 트리시클릭 2,4-디아미노-ｌ,3,5-트리아진 유도체
|
|
UY31968A
(es)
|
2008-07-09 |
2010-01-29 |
Sanofi Aventis |
Nuevos derivados heterocíclicos, sus procesos para su preparación, y sus usos terapéuticos
|
|
CA2729045A1
(en)
*
|
2008-07-31 |
2010-02-04 |
Philippe Bergeron |
Pyrimidine compounds, compositions and methods of use
|
|
MX2011002312A
(es)
*
|
2008-09-03 |
2011-04-26 |
Vertex Pharma |
Co-cristales y formulaciones farmaceuticas que comprenden los mismos.
|
|
JP2012501654A
(ja)
*
|
2008-09-05 |
2012-01-26 |
アビラ セラピューティクス， インコーポレイテッド |
不可逆的インヒビターの設計のためのアルゴリズム
|
|
CN104230901A
(zh)
*
|
2008-09-15 |
2014-12-24 |
加利福尼亚大学董事会 |
用于调节ire1、src和abl活性的方法和组合物
|
|
BRPI0919488A2
(pt)
*
|
2008-09-30 |
2015-12-01 |
Astrazeneca Ab |
composto, uso de um composto, método para tratar câncer em um animal de sangue quente, composição farmacêutica, e, processo para preparar um composto
|
|
US8759362B2
(en)
*
|
2008-10-24 |
2014-06-24 |
Purdue Pharma L.P. |
Bicycloheteroaryl compounds and their use as TRPV1 ligands
|
|
WO2010056758A1
(en)
*
|
2008-11-12 |
2010-05-20 |
Yangbo Feng |
Quinazoline derivatives as kinase inhibitors
|
|
US9023834B2
(en)
|
2008-11-13 |
2015-05-05 |
Taigen Biotechnology Co., Ltd. |
Lyophilization formulation
|
|
WO2010068601A1
(en)
|
2008-12-08 |
2010-06-17 |
Sanofi-Aventis |
A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
|
|
PA8851101A1
(es)
|
2008-12-16 |
2010-07-27 |
Lilly Co Eli |
Compuesto amino pirazol
|
|
ES2422263T3
(es)
*
|
2008-12-19 |
2013-09-10 |
Nerviano Medical Sciences Srl |
Pirazoles bicíclicos como inhibidores de la proteinquinasa
|
|
RU2535032C2
(ru)
|
2008-12-22 |
2014-12-10 |
Милленниум Фармасьютикалз, Инк. |
Сочетание ингибиторов аврора киназы и анти-cd 20 антител
|
|
US8809343B2
(en)
|
2008-12-26 |
2014-08-19 |
Fudan University |
Pyrimidine derivative, preparation method and use thereof
|
|
WO2010099217A1
(en)
|
2009-02-25 |
2010-09-02 |
Braincells, Inc. |
Modulation of neurogenesis using d-cycloserine combinations
|
|
MY159327A
(en)
*
|
2009-02-27 |
2016-12-25 |
Ambit Biosciences Corp |
Jak kinase modulating quinazoline derivatives and methods of use thereof
|
|
CA2660962A1
(en)
|
2009-03-31 |
2010-09-30 |
Astellas Pharma Inc. |
Novel pharmaceutical composition for treatment of schizophrenia
|
|
US8399663B2
(en)
|
2009-04-03 |
2013-03-19 |
Astellas Pharma Inc. |
Salt of 1,3,5-triazine-2,4,6-triamine derivative
|
|
JO3635B1
(ar)
|
2009-05-18 |
2020-08-27 |
Millennium Pharm Inc |
مركبات صيدلانية صلبة وطرق لانتاجها
|
|
WO2010144338A1
(en)
*
|
2009-06-08 |
2010-12-16 |
Abraxis Bioscience, Llc |
Triazine derivatives and their therapeutical applications
|
|
BRPI1010887A2
(pt)
*
|
2009-06-08 |
2016-12-27 |
California Capital Equity Llc |
derivados de triazina e suas aplicações terapêuticas.
|
|
WO2010144522A1
(en)
*
|
2009-06-09 |
2010-12-16 |
Abraxis Bioscience, Llc |
Ureidophenyl substituted triazine derivatives and their therapeutical applications
|
|
EP2440053A4
(en)
*
|
2009-06-09 |
2012-10-31 |
California Capital Equity Llc |
BENZYL SUBSTITUTED TRIAZINE DERIVATIVES AND THERAPEUTIC APPLICATIONS THEREOF
|
|
JP5785940B2
(ja)
*
|
2009-06-09 |
2015-09-30 |
アブラクシス バイオサイエンス， エルエルシー |
トリアジン誘導体類及びそれらの治療応用
|
|
EP2440055B1
(en)
*
|
2009-06-09 |
2015-03-11 |
California Capital Equity, LLC |
Styryl-triazine derivatives and their therapeutical applications
|
|
EP2443106A1
(en)
*
|
2009-06-18 |
2012-04-25 |
Cellzome Limited |
Heterocyclylaminopyrimidines as kinase inhibitors
|
|
TWI468402B
(zh)
*
|
2009-07-31 |
2015-01-11 |
必治妥美雅史谷比公司 |
降低β－類澱粉生成之化合物
|
|
US8637525B2
(en)
|
2009-07-31 |
2014-01-28 |
Bristol-Myers Squibb Company |
Compounds for the reduction of beta-amyloid production
|
|
KR20120060207A
(ko)
|
2009-08-26 |
2012-06-11 |
사노피 |
신규한 결정성 헤테로방향족 플루오로글리코시드 수화물, 이들 화합물을 포함하는 약제 및 이들의 용도
|
|
US9556426B2
(en)
|
2009-09-16 |
2017-01-31 |
Celgene Avilomics Research, Inc. |
Protein kinase conjugates and inhibitors
|
|
KR102077004B1
(ko)
*
|
2009-11-13 |
2020-02-13 |
인튜어티브 서지컬 오퍼레이션즈 인코포레이티드 |
여분의 닫힘 메커니즘을 구비한 단부 작동기
|
|
WO2011090738A2
(en)
|
2009-12-29 |
2011-07-28 |
Dana-Farber Cancer Institute, Inc. |
Type ii raf kinase inhibitors
|
|
JP2013516422A
(ja)
|
2009-12-30 |
2013-05-13 |
アビラ セラピューティクス， インコーポレイテッド |
タンパク質のリガンド−指向性共有的修飾
|
|
SA111320200B1
(ar)
*
|
2010-02-17 |
2014-02-16 |
ديبيوفارم اس ايه |
مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة
|
|
BR112012020557A8
(pt)
|
2010-02-19 |
2018-01-02 |
Millennium Pharm Inc |
formas cristalinas de 4-{[9-cloro-7-(2-flúor-6-metoifenil)-5h-pirimido[5,4-d][2]benzazepin-2-il]amino}-2-metoxibenzoato de sódio
|
|
WO2011107494A1
(de)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
US20130059830A1
(en)
*
|
2010-05-20 |
2013-03-07 |
Fa-Xiang Ding |
Novel prolylcarboxypeptidase inhibitors
|
|
US8927547B2
(en)
|
2010-05-21 |
2015-01-06 |
Noviga Research Ab |
Pyrimidine derivatives
|
|
ES2577829T3
(es)
|
2010-06-04 |
2016-07-19 |
F. Hoffmann-La Roche Ag |
Derivados de aminopirimidina como moduladores de la LRRK2
|
|
EP2582709B1
(de)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
|
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
|
BR112013002164B1
(pt)
|
2010-07-29 |
2021-11-09 |
Oryzon Genomics S.A. |
Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
|
|
EP2663553B1
(en)
*
|
2010-09-01 |
2015-08-26 |
Ambit Biosciences Corporation |
Quinoline and isoquinoline derivatives for use as jak modulators
|
|
AU2011296046B2
(en)
*
|
2010-09-01 |
2015-05-14 |
Ambit Biosciences Corporation |
Hydrobromide salts of a pyrazolylaminoquinazoline
|
|
US20130225614A1
(en)
*
|
2010-09-01 |
2013-08-29 |
Ambit Biosciences Corporation |
4-azolylaminoquinazoline derivatives and methods of use thereof
|
|
EP2611793A1
(en)
*
|
2010-09-01 |
2013-07-10 |
Ambit Biosciences Corporation |
2-cycloquinazoline derivatives and methods of use thereof
|
|
WO2012030918A1
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Adenosine a3 receptor modulating compounds and methods of use thereof
|
|
WO2012030948A1
(en)
*
|
2010-09-01 |
2012-03-08 |
Ambit Biosciences Corporation |
Quinazoline compounds and methods of use thereof
|
|
AU2011296078B2
(en)
*
|
2010-09-01 |
2015-06-18 |
Ambit Biosciences Corporation |
An optically active pyrazolylaminoquinazoline, and pharmaceutical compositions and methods of use thereof
|
|
WO2012059932A1
(en)
|
2010-11-01 |
2012-05-10 |
Aurigene Discovery Technologies Limited |
2, 4 -diaminopyrimidine derivatives as protein kinase inhibitors
|
|
NO2638031T3
(https=)
|
2010-11-10 |
2018-03-10 |
|
|
|
WO2012120058A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
|
EP2766349B1
(de)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683702B1
(de)
|
2011-03-08 |
2014-12-24 |
Sanofi |
Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683699B1
(de)
|
2011-03-08 |
2015-06-24 |
Sanofi |
Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120056A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
WO2012120051A1
(de)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
|
|
EP2683704B1
(de)
|
2011-03-08 |
2014-12-17 |
Sanofi |
Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
|
|
DK2688883T3
(en)
|
2011-03-24 |
2016-09-05 |
Noviga Res Ab |
pyrimidine
|
|
WO2013026914A1
(en)
*
|
2011-08-25 |
2013-02-28 |
F. Hoffmann-La Roche Ag |
Serine/threonine pak1 inhibitors
|
|
WO2013037390A1
(en)
|
2011-09-12 |
2013-03-21 |
Sanofi |
6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
EP2758402B9
(en)
*
|
2011-09-22 |
2016-09-14 |
Pfizer Inc |
Pyrrolopyrimidine and purine derivatives
|
|
BR112014007310A2
(pt)
|
2011-09-27 |
2017-04-04 |
Novartis Ag |
3-pirimidin-4-il-oxazolidin-2-onas como inibidores de idh mutante
|
|
WO2013045413A1
(en)
|
2011-09-27 |
2013-04-04 |
Sanofi |
6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
|
|
US9382239B2
(en)
|
2011-11-17 |
2016-07-05 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of c-Jun-N-terminal kinase (JNK)
|
|
CN104011050A
(zh)
|
2011-12-22 |
2014-08-27 |
霍夫曼-拉罗奇有限公司 |
作为丝氨酸/苏氨酸激酶抑制剂的2,4-二氨基-嘧啶衍生物
|
|
AU2013221286B2
(en)
*
|
2012-02-17 |
2017-06-15 |
Abbvie Inc. |
Diaminopyrimidines useful as inhibitors of the human respiratory syncytial virus (RSV)
|
|
UY34632A
(es)
|
2012-02-24 |
2013-05-31 |
Novartis Ag |
Compuestos de oxazolidin- 2- ona y usos de los mismos
|
|
TWI485146B
(zh)
*
|
2012-02-29 |
2015-05-21 |
Taiho Pharmaceutical Co Ltd |
Novel piperidine compounds or salts thereof
|
|
WO2013138617A1
(en)
|
2012-03-16 |
2013-09-19 |
Axikin Pharmaceuticals, Inc. |
3,5-diaminopyrazole kinase inhibitors
|
|
US20130303519A1
(en)
|
2012-03-20 |
2013-11-14 |
Millennium Pharmaceuticals, Inc. |
Methods of treating cancer using aurora kinase inhibitors
|
|
MX371331B
(es)
|
2012-04-24 |
2020-01-27 |
Vertex Pharma |
Inhibidores de la proteina cinasa dependiente de acido desoxirribonucleico(adn-pk).
|
|
BR112014029310A2
(pt)
*
|
2012-05-24 |
2018-06-26 |
Cellzome Ltd |
análogos da pirimidina heterocíclica como inibidores da tyk2
|
|
JP6280546B2
(ja)
|
2012-06-26 |
2018-02-14 |
デル マー ファーマシューティカルズ |
ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法
|
|
JP6189434B2
(ja)
*
|
2012-07-10 |
2017-08-30 |
アレス トレーディング ソシエテ アノニム |
ピリミジンピラゾリル誘導体
|
|
PL2898886T3
(pl)
*
|
2012-09-19 |
2017-06-30 |
Taiho Pharmaceutical Co., Ltd. |
Kompozycja farmaceutyczna do podawania doustnego z polepszoną elucją i/lub wchłanianiem
|
|
US9296733B2
(en)
|
2012-11-12 |
2016-03-29 |
Novartis Ag |
Oxazolidin-2-one-pyrimidine derivative and use thereof for the treatment of conditions, diseases and disorders dependent upon PI3 kinases
|
|
CN103059002B
(zh)
*
|
2012-12-31 |
2015-04-22 |
中山大学 |
具有Aurora激酶抑制活性的嘧啶衍生物及其制备方法以及应用
|
|
CN103191120B
(zh)
*
|
2012-12-31 |
2015-11-25 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗肿瘤的药物中的用途
|
|
CN103202843B
(zh)
*
|
2012-12-31 |
2015-04-29 |
刘强 |
一种嘧啶衍生物在制备预防和/或治疗和/或辅助治疗癌症的药物中的用途
|
|
CN103910716A
(zh)
*
|
2013-01-07 |
2014-07-09 |
华东理工大学 |
2,4-二取代-环烷基[d]嘧啶类化合物及其用途
|
|
ME03336B
(me)
|
2013-03-12 |
2019-10-20 |
Vertex Pharma |
Inhibitori dnk-pk
|
|
JP6387360B2
(ja)
|
2013-03-14 |
2018-09-05 |
ノバルティス アーゲー |
変異ｉｄｈの阻害薬としての３−ピリミジン−４−イル−オキサゾリジン−２−オン
|
|
WO2014145485A2
(en)
|
2013-03-15 |
2014-09-18 |
The Trustees Of Columbia University In The City Of New York |
Map kinase modulators and uses thereof
|
|
WO2014153509A1
(en)
|
2013-03-22 |
2014-09-25 |
Millennium Pharmaceuticals, Inc. |
Combination of catalytic mtorc 1/2 inhibitors and selective inhibitors of aurora a kinase
|
|
WO2015003355A2
(en)
*
|
2013-07-11 |
2015-01-15 |
Agios Pharmaceuticals, Inc. |
Therapeutically active compounds and their methods of use
|
|
CN112472699A
(zh)
|
2013-07-26 |
2021-03-12 |
种族肿瘤学公司 |
改善比生群及衍生物的治疗益处的组合方法
|
|
WO2015028848A1
(en)
*
|
2013-09-02 |
2015-03-05 |
Piramal Enterprises Limited |
Bicyclic heterocyclic compounds as multi-kinase inhibitors
|
|
NZ631142A
(en)
|
2013-09-18 |
2016-03-31 |
Axikin Pharmaceuticals Inc |
Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors
|
|
JP6408569B2
(ja)
|
2013-10-17 |
2018-10-17 |
バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ |
Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
|
|
WO2015058126A1
(en)
|
2013-10-18 |
2015-04-23 |
Syros Pharmaceuticals, Inc. |
Heteroaromatic compounds useful for the treatment of prolferative diseases
|
|
EP3057956B1
(en)
|
2013-10-18 |
2021-05-05 |
Dana-Farber Cancer Institute, Inc. |
Polycyclic inhibitors of cyclin-dependent kinase 7 (cdk7)
|
|
PL3089971T3
(pl)
|
2014-01-01 |
2021-01-25 |
Medivation Technologies Llc |
Związki i sposoby ich zastosowania
|
|
US10258585B2
(en)
|
2014-03-13 |
2019-04-16 |
Neuroderm, Ltd. |
DOPA decarboxylase inhibitor compositions
|
|
DK3116475T3
(da)
|
2014-03-13 |
2020-12-07 |
Neuroderm Ltd |
Dopa-decarboxylasehæmmersammensætninger
|
|
WO2015148867A1
(en)
*
|
2014-03-28 |
2015-10-01 |
Calitor Sciences, Llc |
Substituted heteroaryl compounds and methods of use
|
|
US10167257B2
(en)
|
2014-04-04 |
2019-01-01 |
Iomet Pharma Ltd. |
Indole derivatives for use in medicine
|
|
CA2945263A1
(en)
|
2014-04-09 |
2015-10-15 |
Christopher Rudd |
Use of gsk-3 inhibitors or activators which modulate pd-1 or t-bet expression to modulate t cell immunity
|
|
CN105367555B
(zh)
*
|
2014-08-07 |
2019-06-25 |
广东东阳光药业有限公司 |
取代的杂芳基化合物及其组合物和用途
|
|
HUE054848T2
(hu)
|
2014-10-13 |
2021-09-28 |
Yuhan Corp |
Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
|
|
JP6854762B2
(ja)
|
2014-12-23 |
2021-04-07 |
ダナ−ファーバー キャンサー インスティテュート， インコーポレイテッド |
サイクリン依存性キナーゼ７（ｃｄｋ７）の阻害剤
|
|
TWI703133B
(zh)
|
2014-12-23 |
2020-09-01 |
美商艾克斯基製藥公司 |
３,５-二胺基吡唑激酶抑制劑
|
|
US10227343B2
(en)
*
|
2015-01-30 |
2019-03-12 |
Vanderbilt University |
Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
USRE50776E1
(en)
|
2015-03-27 |
2026-02-03 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
WO2016166604A1
(en)
|
2015-04-17 |
2016-10-20 |
Ludwig Institute For Cancer Research Ltd |
Plk4 inhibitors
|
|
ES2753159T3
(es)
|
2015-05-28 |
2020-04-07 |
Theravance Biopharma R&D Ip Llc |
Compuestos de naftiridina como inhibidores de quinasa JAK
|
|
JP2018135268A
(ja)
*
|
2015-06-05 |
2018-08-30 |
大日本住友製薬株式会社 |
新規ヘテロアリールアミノ−３−ピラゾール誘導体およびその薬理学上許容される塩
|
|
WO2017015316A1
(en)
|
2015-07-21 |
2017-01-26 |
Millennium Pharmaceuticals, Inc. |
Administration of aurora kinase inhibitor and chemotherapeutic agents
|
|
AU2016319125B2
(en)
|
2015-09-09 |
2021-04-08 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinases
|
|
JP2018527362A
(ja)
|
2015-09-11 |
2018-09-20 |
サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． |
置換されたヘテロアリール化合物および使用方法
|
|
IL294124B2
(en)
|
2015-12-10 |
2024-02-01 |
Ptc Therapeutics Inc |
Methods for treating huntington's disease
|
|
CN105399695B
(zh)
*
|
2015-12-11 |
2019-04-19 |
浙江大学 |
三嗪类化合物及其制备方法和用途
|
|
CN105384702B
(zh)
*
|
2015-12-11 |
2018-04-10 |
浙江大学 |
三取代均三嗪类化合物及其制备方法
|
|
CN105503754B
(zh)
*
|
2015-12-11 |
2017-11-17 |
浙江大学 |
2‑氨基‑4‑苄基‑6‑吗啉‑1,3,5‑三嗪及其制备和应用
|
|
EP3390387B1
(en)
|
2015-12-18 |
2021-11-17 |
Bayer Pharma Aktiengesellschaft |
Heteroarylbenzimidazole compounds
|
|
WO2017160569A1
(en)
|
2016-03-14 |
2017-09-21 |
Afferent Pharmaceuticals Inc. |
Pyrimidines and variants thereof, and uses therefor
|
|
AU2017237929B2
(en)
|
2016-03-25 |
2021-04-15 |
Afferent Pharmaceuticals Inc. |
Pyrimidines and variants thereof, and uses therefor
|
|
CA3020506A1
(en)
|
2016-04-28 |
2017-11-02 |
Theravance Biopharma R&D Ip, Llc |
Pyrimidine compounds as jak kinase inhibitors
|
|
WO2017207534A1
(en)
|
2016-06-03 |
2017-12-07 |
Bayer Pharma Aktiengesellschaft |
Substituted heteroarylbenzimidazole compounds
|
|
EP3518931A4
(en)
|
2016-09-27 |
2020-05-13 |
Vertex Pharmaceuticals Incorporated |
METHOD FOR TREATING CANCER WITH A COMBINATION OF DNA-DAMAGING SUBSTANCES AND DNA-PK INHIBITORS
|
|
US10858319B2
(en)
|
2016-10-03 |
2020-12-08 |
Iomet Pharma Ltd. |
Indole derivatives for use in medicine
|
|
US10968227B2
(en)
*
|
2016-11-08 |
2021-04-06 |
Vanderbilt University |
Isoquinoline ether compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
|
|
CN108239071B
(zh)
*
|
2016-12-27 |
2020-12-04 |
沈阳药科大学 |
酰胺及硫代酰胺类衍生物及其制备方法和应用
|
|
FR3064275B1
(fr)
|
2017-03-21 |
2019-06-07 |
Arkema France |
Procede de chauffage et/ou climatisation d'un vehicule
|
|
CR20190580A
(es)
|
2017-05-30 |
2020-02-10 |
Basf Se |
Compuestos de piridina y pirazina
|
|
US11407753B2
(en)
|
2017-06-05 |
2022-08-09 |
Ptc Therapeutics, Inc. |
Compounds for treating Huntington's disease
|
|
US11382918B2
(en)
|
2017-06-28 |
2022-07-12 |
Ptc Therapeutics, Inc. |
Methods for treating Huntington's Disease
|
|
WO2019005993A1
(en)
|
2017-06-28 |
2019-01-03 |
Ptc Therapeutics, Inc. |
METHODS OF TREATING HUNTINGTON'S DISEASE
|
|
KR102563325B1
(ko)
|
2017-06-30 |
2023-08-03 |
베이징 타이드 파마슈티컬 코퍼레이션 리미티드 |
Ｒｈｏ-관련 단백질 키나아제 억제제, Ｒｈｏ-관련 단백질 키나아제 억제제를 함유하는 약학 조성물, 제조 방법 및 약학 조성물의 용도
|
|
CN110582491B
(zh)
|
2017-06-30 |
2023-09-29 |
北京泰德制药股份有限公司 |
Rho相关蛋白激酶抑制剂、包含其的药物组合物及其制备方法和用途
|
|
JP7311228B2
(ja)
|
2017-06-30 |
2023-07-19 |
ベイジン タイド ファーマシューティカル カンパニー リミテッド |
Ｒｈｏ－関連プロテインキナーゼ阻害剤、それを含む医薬組成物並びにその調製方法及び使用
|
|
WO2019046163A1
(en)
*
|
2017-08-28 |
2019-03-07 |
Zhihong Chen |
SUBSTITUTED PYRIMIDINES, PHARMACEUTICAL COMPOSITIONS AND ASSOCIATED THERAPEUTIC METHODS
|
|
EP3676264A1
(en)
*
|
2017-08-28 |
2020-07-08 |
Acurastem Inc. |
Pikfyve kinase inhibitors
|
|
SG11202001706RA
(en)
|
2017-10-27 |
2020-03-30 |
Theravance Biopharma R&D Ip Llc |
Pyrimidine compound as jak kinase inhibitor
|
|
MX2020004536A
(es)
*
|
2017-11-23 |
2020-08-03 |
Biomed X Gmbh |
Derivados de pirimidina como inhibidores del receptor de tropomiosina quinasa (trka).
|
|
EP3720560A4
(en)
*
|
2017-12-06 |
2022-01-05 |
Ludwig Institute for Cancer Research Ltd |
METHOD OF TREATMENT OF CANCER WITH PLK4 INHIBITORS
|
|
EP3765459A1
(en)
|
2018-03-13 |
2021-01-20 |
Shire Human Genetic Therapies, Inc. |
Substituted imidazopyridines as inhibitors of plasma kallikrein and uses thereof
|
|
MX2020009957A
(es)
|
2018-03-27 |
2021-01-15 |
Ptc Therapeutics Inc |
Compuestos para el tratamiento de enfermedad de hungtinton.
|
|
EP3810132A4
(en)
|
2018-06-25 |
2022-06-22 |
Dana-Farber Cancer Institute, Inc. |
TAIRE FAMILY KINASE INHIBITORS AND RELATED USES
|
|
EP3814345B8
(en)
|
2018-06-27 |
2024-10-30 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
EP3814360B8
(en)
|
2018-06-27 |
2024-11-06 |
PTC Therapeutics, Inc. |
Heteroaryl compounds for treating huntington's disease
|
|
PL3814357T3
(pl)
|
2018-06-27 |
2024-09-16 |
Ptc Therapeutics, Inc. |
Związki heterocykliczne i heteroarylowe do leczenia choroby huntingtona
|
|
AU2019318209B2
(en)
|
2018-08-10 |
2025-09-25 |
Diapin Therapeutics, Llc |
Tri-peptides and treatment of metabolic, cardiovascular and inflammatory disorders
|
|
WO2020108613A1
(zh)
*
|
2018-11-30 |
2020-06-04 |
江苏豪森药业集团有限公司 |
杂芳类衍生物调节剂、其制备方法和应用
|
|
US12281126B2
(en)
|
2018-12-28 |
2025-04-22 |
Dana-Farber Cancer Institute, Inc. |
Inhibitors of cyclin-dependent kinase 7 and uses thereof
|
|
TW202106681A
(zh)
|
2019-04-24 |
2021-02-16 |
美商施萬生物製藥研發Ｉｐ有限責任公司 |
用於治療皮膚疾病之嘧啶jak抑制劑
|
|
PL3958969T3
(pl)
|
2019-04-24 |
2024-05-20 |
Theravance Biopharma R&D Ip, Llc |
Estrowe i węglanowe związki pirymidynowe jako inhibitory kinaz
|
|
WO2020231977A1
(en)
|
2019-05-13 |
2020-11-19 |
Ptc Therapeutics, Inc. |
Compounds for treating huntington's disease
|
|
US12428395B2
(en)
|
2019-08-01 |
2025-09-30 |
Sperogenix Therapeutics Limited |
Heterocyclic compounds as kinase inhibitor and uses thereof
|
|
EP4031245A1
(en)
|
2019-09-18 |
2022-07-27 |
Takeda Pharmaceutical Company Limited |
Heteroaryl plasma kallikrein inhibitors
|
|
DK4031547T3
(da)
|
2019-09-18 |
2024-09-09 |
Takeda Pharmaceuticals Co |
Plasmakallikreininhibitorer og anvendelser deraf
|
|
CN110483493A
(zh)
*
|
2019-09-19 |
2019-11-22 |
广东工业大学 |
一种二唑类衍生物及其制备方法和应用
|
|
TWI885039B
(zh)
|
2020-01-13 |
2025-06-01 |
美商邊際分析公司 |
經取代吡唑并嘧啶及其用途
|
|
US11844754B2
(en)
|
2020-11-17 |
2023-12-19 |
Neuroderm, Ltd. |
Methods for treatment of Parkinson's disease
|
|
US11331293B1
(en)
|
2020-11-17 |
2022-05-17 |
Neuroderm, Ltd. |
Method for treatment of Parkinson's disease
|
|
US11213502B1
(en)
|
2020-11-17 |
2022-01-04 |
Neuroderm, Ltd. |
Method for treatment of parkinson's disease
|
|
TW202237119A
(zh)
|
2020-12-10 |
2022-10-01 |
美商住友製藥腫瘤公司 |
Ａｌｋ﹘５抑制劑和彼之用途
|
|
US20240199613A1
(en)
*
|
2021-03-17 |
2024-06-20 |
Takeda Pharmaceutical Company Limited |
Polycyclic inhibitors of plasma kallikrein
|
|
JP2024511012A
(ja)
*
|
2021-03-24 |
2024-03-12 |
アトス セラピューティクス，インコーポレイテッド |
キナーゼ関連疾患の処置のための小分子
|
|
CN117355304A
(zh)
*
|
2021-03-26 |
2024-01-05 |
住友制药肿瘤公司 |
Alk-5抑制剂及其用途
|
|
AU2022243600A1
(en)
*
|
2021-03-26 |
2023-10-12 |
Sumitomo Pharma Oncology, Inc. |
Alk-5 inhibitors and uses thereof
|
|
JP7717842B2
(ja)
|
2021-05-11 |
2025-08-04 |
オリック ファーマシューティカルズ，インク． |
ポロ様キナーゼ４阻害剤
|
|
US11932648B2
(en)
|
2021-06-28 |
2024-03-19 |
Blueprint Medicines Corporation |
CDK2 inhibitors
|
|
KR102692529B1
(ko)
*
|
2021-07-01 |
2024-08-08 |
한국원자력의학원 |
Mastl-pp2a를 표적화하는 암의 예방 또는 치료용 약학적 조성물
|
|
CN116354938B
(zh)
*
|
2021-12-28 |
2024-02-20 |
沈阳药科大学 |
一类喹唑啉衍生物与其类似物的制备方法及应用
|
|
CN114276302B
(zh)
*
|
2022-01-11 |
2023-07-25 |
山东百启生物医药有限公司 |
一种制备2,4-二氨基喹唑啉衍生物的方法
|
|
CN116813595B
(zh)
*
|
2022-03-28 |
2025-07-18 |
上海医药工业研究院有限公司 |
喹唑啉类衍生物、其制备方法、药物组合物及应用
|
|
WO2024003773A1
(en)
|
2022-07-01 |
2024-01-04 |
Pfizer Inc. |
2,7-naphthyridine compounds as mastl inhibitors
|
|
CN117736198A
(zh)
*
|
2022-09-21 |
2024-03-22 |
科辉智药生物科技(深圳)有限公司 |
大环含氮冠醚化合物及其作为蛋白激酶抑制剂的应用
|
|
CN115403568B
(zh)
*
|
2022-09-21 |
2023-09-29 |
中山大学 |
一种喹唑啉类Aurora A共价抑制剂及其制备方法和应用
|
|
WO2024178335A2
(en)
*
|
2023-02-23 |
2024-08-29 |
Accutar Biotechnology, Inc. |
Novel macrocyclic aminopyrazole compounds as cdk2 inhibitors
|
|
US12161612B2
(en)
|
2023-04-14 |
2024-12-10 |
Neuroderm, Ltd. |
Methods and compositions for reducing symptoms of Parkinson's disease
|
|
WO2026024674A1
(en)
|
2024-07-22 |
2026-01-29 |
Genesis Therapeutics, Inc. |
Methods of treating skp2-associated cancers
|